<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Obesity in adults: Etiologies and risk factors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Obesity in adults: Etiologies and risk factors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Obesity in adults: Etiologies and risk factors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leigh Perreault, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel Bessesen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Xavier Pi-Sunyer, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Obesity is a chronic, often progressive metabolic disease, associated with an increase in mortality and morbidity, that is increasing in prevalence in adults. This topic will review factors that are associated with and promote the development of obesity. The etiology of obesity in children and adolescents is reviewed separately. The specific genetic causes of obesity, as well as the evaluation, prevalence, and treatment of obesity in adults, are also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5874.html" rel="external">"Definition, epidemiology, and etiology of obesity in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5372.html" rel="external">"Obesity in adults: Prevalence, screening, and evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p></p><p class="headingAnchor" id="H2467228029"><span class="h1">OBESITY AS A DISEASE</span><span class="headingEndMark"> — </span>Obesity is the result of long-term positive energy balance where energy intake exceeds energy expenditure [<a href="#rid1">1</a>]. Many health care providers and patients share the belief that obesity is the product of poor lifestyle choices that are under the voluntary control of affected individuals. This can lead to stigmatization of people with obesity and a reluctance to use the full range of available treatments [<a href="#rid2">2</a>]. It is now generally recognized that body weight is a physiologically regulated parameter, and obesity is recognized as a disease of body weight regulation, much as diabetes is a disorder of glucose regulation and hypertension is a disorder of blood pressure regulation [<a href="#rid3">3,4</a>]. There are many factors that may contribute to the development of obesity, including genetics, age, lifestyle factors, medications, and hormonal issues.</p><p class="headingAnchor" id="H951900045"><span class="h1">GENETICS OF OBESITY</span><span class="headingEndMark"> — </span>Studies suggest that the genetic contribution to adult body mass index (BMI) is 40 to 70 percent in most individuals [<a href="#rid5">5,6</a>]. If a young person has one biological parent with obesity, their risk of obesity is increased three- to fourfold compared with those who do not [<a href="#rid7">7</a>]. Having two biological parents with obesity is associated with a greater than 10-fold increased risk of obesity. However, despite the identification of hundreds of genetic loci associated with obesity in genome-wide association studies, genetic testing of patients with “common” (ie, not syndromic) obesity is not clinically useful [<a href="#rid8">8</a>].</p><p>Rare forms of obesity result from certain genetic abnormalities, including Prader-Willi syndrome, Bardet-Biedl syndrome, and the monogenic obesities: melanocortin 4 receptor deficiency (the most common), leptin and leptin receptor deficiencies, and proopiomelanocortin (POMC) deficiency [<a href="#rid9">9</a>]. Monogenic and syndromic obesity typically present as early-onset (&lt;5 years of age) severe obesity, and they are associated with other signs and symptoms.</p><p>A detailed discussion of the genetic contribution to obesity, including syndromic and monogenic forms of obesity, is found elsewhere. (See  <a class="medical medical_review" href="/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology"</a>.)</p><p class="headingAnchor" id="H2430233868"><span class="h1">DEMOGRAPHIC FACTORS</span><span class="headingEndMark"> — </span>In the United States, there are regional variations in the prevalence of obesity, with rates ranging from 13 to 50 percent in different counties. Socioeconomic and environmental factors account for 33 and 15.5 percent of the variance, respectively [<a href="#rid10">10</a>]. Obesity prevalence is lowest among those with the highest income and the most education [<a href="#rid11">11</a>]; these relationships are independent of race and ethnicity. In addition, the prevalence of obesity varies among different United States populations. As an example, in 2017 to 2018, the lowest prevalence of obesity was among non-Hispanic Asian adults (17 percent) compared with non-Hispanic White adults (42 percent), Hispanic adults (44 percent), and non-Hispanic Black adults (50 percent)  (<a class="graphic graphic_figure graphicRef132470" href="/d/graphic/132470.html" rel="external">figure 1</a>) [<a href="#rid12">12</a>]. This is likely related to the social determinants of health, such as elements of the built environment that promote physical activity (eg, availability of sidewalks and playgrounds) [<a href="#rid13">13</a>] and the food environment, that promote or inhibit the consumption of a healthy diet [<a href="#rid14">14</a>].</p><p>Further discussion of the epidemiology of obesity is found elsewhere. (See  <a class="medical medical_review" href="/d/html/5372.html" rel="external">"Obesity in adults: Prevalence, screening, and evaluation", section on 'Prevalence'</a>.)</p><p class="headingAnchor" id="H891152207"><span class="h1">AGE AND WEIGHT</span><span class="headingEndMark"> — </span>Prenatal and childhood factors, as well as weight trajectories observed with aging, can predispose to the development of adult obesity.</p><p class="headingAnchor" id="H1448892763"><span class="h2">Fetal and childhood factors</span><span class="headingEndMark"> — </span>Early life events can predispose to obesity in adult life. Both maternal obesity and undernutrition are associated with adult obesity in offspring [<a href="#rid15">15</a>]. Undernutrition in the first trimester followed by excessive nutrient availability in the postpartum period and infancy are particularly associated with obesity in adulthood [<a href="#rid16">16</a>]. Elevated maternal body mass index (BMI) has been associated with increased fat mass in infants and an increased risk of obesity and metabolic disease in adult offspring [<a href="#rid17">17</a>]. Excessive gestational weight gain, gestational diabetes, and maternal type 2 diabetes can all predispose to adult obesity in offspring, demonstrating that both maternal BMI and glycemia play a role in determining adiposity in offspring [<a href="#rid18">18</a>].</p><p>Maternal obesity is believed to alter the development of brain regions involved in body weight regulation and peripheral tissues, including adipose tissue and liver, through epigenetic changes that alter gene expression in these tissues [<a href="#rid19">19</a>]. These epigenetic changes, potentially the result of increased delivery of nutrients from the mother to the developing fetus, promote increased appetite and fat storage in offspring. Gestational, infancy, and childhood contributions to adult obesity are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5874.html" rel="external">"Definition, epidemiology, and etiology of obesity in children and adolescents", section on 'Persistence into adulthood'</a> and  <a class="medical medical_review" href="/d/html/5874.html" rel="external">"Definition, epidemiology, and etiology of obesity in children and adolescents", section on 'Metabolic programming'</a>.)</p><p class="headingAnchor" id="H2227629763"><span class="h2">Weight gain in adulthood</span><span class="headingEndMark"> — </span>Adults tend to gradually gain weight between the ages of 20 to 65. As a result, the long-term risk of becoming overweight (BMI ≥25 kg/m<sup>2</sup>) or obese (BMI ≥30 kg/m<sup>2</sup>) over the course of one's life are high. In a prospective cohort study including 4117 normal-weight United States adults ages 30 to 59 years at baseline [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Within four years, 14 to 19 percent of females and 26 to 30 percent of males became overweight; 5 to 9 percent of all subjects developed obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Within 30 years, more than 50 percent of participants became overweight; approximately 30 percent of females and 25 percent of males developed obesity.</p><p></p><p>Between the ages of 20 to 65, a typical adult will consume more than 17,000 pounds of food while only gaining about one to two pounds per year [<a href="#rid21">21</a>]. It is estimated that the energy imbalance responsible for the increased prevalence of obesity over the last 30 years is just 100 kcal/day [<a href="#rid22">22</a>], demonstrating that even a small daily positive energy balance would lead to clinically significant weight gain if sustained for many years. This degree of energy imbalance is difficult for an individual to perceive; clinicians routinely encounter patients with weight gain despite reporting eating a calorie-restricted diet and exercising regularly. Such individuals have been studied under controlled conditions, and results reveal that they underreport energy intake [<a href="#rid23">23</a>]. In fact, underreporting of energy intake and overreporting of physical activity is found consistently in studies [<a href="#rid24">24</a>]. Rather than challenging their patients’ self-reported caloric intake and physical activity, clinicians can reflect on how difficult weight loss is in the face of strong biological systems that defend weight and promote weight gain, and also educate and encourage patients about the value of self-monitoring to gain insight into opportunities for lifestyle change.</p><p>Weight tends to rise until roughly the age of 65. After that, weight falls at a rate of 0.65 kg/year on average, although this decline is quite variable between individuals [<a href="#rid25">25</a>]. This occurs in part due to a decrease in muscle mass (sarcopenia), which begins even in the 40s. Fat mass, by contrast, continues to increase into old age, resulting in a decreased association of BMI with fat mass [<a href="#rid26">26</a>]. Energy expenditure declines with aging; -165 kcal/day/decade of life in males and -103 kcal/day/decade of life in females [<a href="#rid27">27</a>]. This is due to a decline in resting energy expenditure (REE) as well as decreased energy expended in physical activity. Older individuals report less hunger during dietary restriction and sense hypoglycemia less well than younger people. Taste and smell can become impaired with aging and can also contribute to decreased food consumption (ie, energy intake).</p><p>Further details of energy balance and weight homeostasis are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology", section on 'Physiological processes affecting energy balance'</a>.)</p><p class="headingAnchor" id="H3976859467"><span class="h3">Pregnancy and weight</span><span class="headingEndMark"> — </span>Weight gain is a physiological consequence of a normal pregnancy, but for many individuals, weight gained during pregnancy is not completely lost following delivery, leading to progressive weight gain over multiple pregnancies and, for some, the development of obesity [<a href="#rid28">28</a>]. Individuals experience modest increases in weight and central adiposity following a first pregnancy. These changes can persist and may vary according to race and ethnic background [<a href="#rid29">29,30</a>]. The National Academy of Medicine suggested that pregnancy weight gain goals be tailored to the individual’s pre-pregnancy weight category  (<a class="graphic graphic_table graphicRef75820" href="/d/graphic/75820.html" rel="external">table 1</a>) [<a href="#rid31">31</a>], and the subsequent LifeCycle Project has given further recommendations for individuals in different categories of obesity  (<a class="graphic graphic_table graphicRef127435" href="/d/graphic/127435.html" rel="external">table 2</a>). In the United States, 47 percent of females gain more than the recommended amount during pregnancy  (<a class="graphic graphic_figure graphicRef132306" href="/d/graphic/132306.html" rel="external">figure 2</a>) and individuals who are overweight or obese at baseline are more likely to gain excessive weight gain [<a href="#rid32">32</a>].</p><p>Weight gain and management in pregnancy is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/441.html" rel="external">"Gestational weight gain", section on 'Recommendations for gestational weight gain'</a>.)</p><p class="headingAnchor" id="H2024275125"><span class="h3">Menopause and weight</span><span class="headingEndMark"> — </span>In females, weight gain and increased central fat distribution often occur in the early postmenopausal years [<a href="#rid33">33</a>]. The magnitude of the increase depends upon the method of measurement [<a href="#rid30">30</a>]. The increase in fat mass with preferential accumulation of visceral fat is felt to be due to reductions in energy expenditure in menopause [<a href="#rid34">34</a>]. The increased levels of follicle-stimulating hormone (FSH) that occur with menopause may be involved in this weight gain independent of the fall in estrogen [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause", section on 'Long-term consequences of estrogen deficiency'</a>.)</p><p>In the Study of Women's Health Across the Nation (SWAN) including almost 550 females aged 42 to 52 at baseline, weight, waist circumference, and fat mass (measured with bioelectrical impedance) were followed for six years [<a href="#rid36">36</a>]. Over the study period, there was an average 2.9 kg weight gain, 3.4 kg increase in fat mass, and a 5.7 cm increase in waist circumference. Among study subjects, the rate of waist circumference increase slowed one year after the final menstrual period, whereas fat mass continued to increase without change.</p><p>However, estrogen therapy does not prevent weight gain in postmenopausal females, although it may minimize fat redistribution [<a href="#rid37">37,38</a>]. In a three-year trial including over 800 participants from the Women's Health Initiative (WHI), those who received estrogen and <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> therapy lost less lean muscle mass (-0.04 versus -0.44 kg) and had less change in fat distribution compared with those receiving placebo [<a href="#rid37">37</a>]. However, the effects were small and the clinical benefits unclear. In a metanalysis including 28 randomized trials and over 28,000 participants, the use of post-menopausal estrogen alone or combination estrogen and progesterone was not associated with a change in body weight [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Weight'</a>.)</p><p class="headingAnchor" id="H2453738837"><span class="h1">LIFESTYLE CONTRIBUTORS</span><span class="headingEndMark"> — </span>Weight gain occurs when energy intake exceeds energy expenditure, and lifestyle factors including diet and physical activity impact this balance.</p><p class="headingAnchor" id="H2327854719"><span class="h2">Dietary factors</span><span class="headingEndMark"> — </span>Globally, the food environment has changed dramatically over the last 70 years, providing people access to highly palatable, energy-dense food. It is difficult, however, to get accurate information on energy intake since self-reported dietary data are notoriously unreliable. According to the US Department of Agriculture (USDA) data on the food energy supply, average food intake in the United States has increased over the past several decades. In the 1970s, intake was 2398 kcal/day/person and increased to 2895 kcal/day/person in the 2000s. This increase in energy intake is sufficient to account for the increase in the prevalence of obesity observed over this time [<a href="#rid40">40</a>].</p><p>These USDA data also suggest that Americans are eating more fat, sugar, proteins, and grains and less fruit, vegetables, and dairy than recommended [<a href="#rid40">40,41</a>]. Although dietary macronutrient composition has been evaluated with regards to risk of weight gain, there is no conclusive evidence that a diet high in either fat or carbohydrates is consistently associated with weight gain [<a href="#rid1">1</a>].</p><p>The quality of the diet and its components are being evaluated for their role in weight gain. In a longitudinal study including over 120,000 adults, increase in the intake of specific foods have been associated with either weight gain (eg, potato chips, French fries, processed meats, red meat, sweets and desserts) or protection against weight gain (yogurt, fruit, whole grains, nuts, vegetables)  (<a class="graphic graphic_figure graphicRef132327" href="/d/graphic/132327.html" rel="external">figure 3</a>) [<a href="#rid42">42</a>]. In addition, observational studies have found an association between the consumption of ultraprocessed foods (eg, foods that have undergone multiple physical, biological, and/or chemical processes that are associated with industrial food production and typically contain food additives) with the development of obesity [<a href="#rid43">43</a>]. In a randomized controlled trial including 20 adults comparing two weeks of ad-libitum consumption of an ultraprocessed diet with an unprocessed diet, consumption of an ultraprocessed diet increased energy intake (+508 kcal/day) and weight (+0.9 kg), while consumption of an unprocessed diet decreased weight (-0.9 kg) [<a href="#rid44">44</a>].</p><p>The role of diet and dietary changes in managing obesity are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/5375.html" rel="external">"Obesity in adults: Dietary therapy", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H887218467"><span class="h2">Physical activity and inactivity</span><span class="headingEndMark"> — </span>The most variable component of energy expenditure is energy expended in physical activity. Reductions in habitual levels of physical activity along with increased time spent in sedentary behaviors have been associated with an increased risk of obesity [<a href="#rid45">45</a>]. According to a Surgeon General's Report of Physical Activity, the percent of adult Americans participating in physical activity decreases steadily with age, and reduced energy expenditure in adults and children is predictive of weight gain [<a href="#rid46">46</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Comparing Pima populations living in Mexico and the United States, those living a traditional agrarian lifestyle in remote northern Mexico have low levels of obesity and type 2 diabetes [<a href="#rid47">47</a>]. By contrast, more than 80 percent of the adult Pima population living in Arizona have obesity. In the study, energy expenditure was 3289 kcal/day in the Mexican Pima population compared with 2671 kcal/day in the United States Pima population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occupational physical activity has fallen in the United States over the last 50 years, during which the prevalence of obesity has grown [<a href="#rid48">48</a>]. In 1960, approximately half of the United States workforce was moderately active on the job, but as of 2010, &gt;70 percent of workers were either sedentary or reported a light physical workload. This represents an average decline in work-related energy expenditure of 140 kcal/day in males and 120 kcal/day in females, further contributing to an increasing prevalence of obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In data from the 2003 to 2006 National Health and Nutrition Examination Survey (NHANES), obesity was more strongly related to moderately vigorous physical activity than either TV time or total sedentary time for adults in the United States [<a href="#rid49">49</a>]. Small differences in daily levels of moderately vigorous physical activity (5 to 10 minutes) were associated with relatively large differences in obesity risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Time spent sitting and in sedentary behaviors is associated with adverse metabolic health outcomes such as type 2 diabetes, but the relationship between sedentary behaviors and obesity has been harder to demonstrate [<a href="#rid50">50</a>]. Of all sedentary behaviors, prolonged television watching appears to be the most closely associated with the risk of obesity and diabetes [<a href="#rid51">51</a>]. In the Nurses' Health Study, after adjusting for age, exercise level, and dietary factors, every two-hour increment spent watching television was associated with an increase in the risk of obesity and diabetes (23 percent, 95% CI 17 -30; and 14 percent, 95% CI 5-23, respectively) [<a href="#rid52">52</a>]. Less risk was associated with other sedentary behavior such as sitting at work. The effects of television watching on obesity may be mediated, in part, by increases in energy intake (eg, associated eating behaviors) rather than a decrease in physical activity alone [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity is more prevalent in adults with physical, sensory, or mental health disabilities; those with impaired lower-extremity mobility are at highest risk [<a href="#rid55">55</a>].</p><p></p><p>The role of physical activity in the management of obesity is reviewed separately. (See  <a class="medical medical_review" href="/d/html/5379.html" rel="external">"Obesity in adults: Role of physical activity and exercise"</a>.)</p><p class="headingAnchor" id="H966704276"><span class="h2">Sleep patterns</span><span class="headingEndMark"> — </span>Epidemiological studies show strong and consistent associations between shortened nocturnal sleep time, late bedtime, and nightshift work with the development of obesity, type 2 diabetes mellitus, and related metabolic disorders [<a href="#rid56">56,57</a>]. Although the average adult sleep duration has not changed over the past half-century [<a href="#rid58">58</a>], the number of people performing nightshift work has increased, with many employees working during what is typically considered sleep time [<a href="#rid56">56</a>].</p><p>Individuals who have shortened sleep duration or a nightshift schedule spend more time in sedentary activities and less time in moderate and vigorous physical activity compared with people on a normal sleep schedule. In experimental studies, these changes lead to a reduction in total daily energy expenditure [<a href="#rid59">59,60</a>]. Studies have also shown that with sleep restriction, brain regions associated with food reward are activated and measured food intake, particularly high-fat foods, increases [<a href="#rid61">61</a>]. With sleep restriction, levels of satiety hormones are lower and levels of ghrelin higher. By contrast, extending sleep duration may lead to reduced energy intake [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H35239259"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Despite clear health benefits, smoking cessation is associated with an average weight gain of 2.6 kg [<a href="#rid63">63</a>]. The degree of weight gain is highly variable, with 10 percent of quitters gaining 10 kg at one year. This weight gain may in part be due to a loss of nicotine’s activating effects on proopiomelanocortin (POMC) neurons in the hypothalamus, which decrease food intake [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H1612312650"><span class="h1">MEDICATIONS ASSOCIATED WITH WEIGHT GAIN</span><span class="headingEndMark"> — </span>A variety of medications prescribed for common health problems have been associated with weight gain  (<a class="graphic graphic_table graphicRef132587" href="/d/graphic/132587.html" rel="external">table 3</a>)<strong> </strong>[<a href="#rid65">65</a>]. Within each category, there are alternatives that are either weight-neutral or may promote weight loss.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotic agents</strong> – Antipsychotic drugs have a variable effect on body weight, although many agents are associated with weight gain  (<a class="graphic graphic_table graphicRef132587" href="/d/graphic/132587.html" rel="external">table 3</a>) [<a href="#rid66">66</a>]. Among the conventional (first-generation) antipsychotics, the estimated average weight gain after 10 weeks of therapy was highest for <a class="drug drug_general" data-topicid="9991" href="/d/drug information/9991.html" rel="external">thioridazine</a> (3.2 kg). <a class="drug drug_general" data-topicid="9662" href="/d/drug information/9662.html" rel="external">Molindone</a> did not cause weight gain.</p><p></p><p class="bulletIndent1">Among the atypical (second-generation) antipsychotics, <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> and <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> are associated with the greatest weight gain (4.4 and 4.2 kg, respectively), followed by <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> (2.10 kg) [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/14773.html" rel="external">"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"</a> and  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a>, a mood stabilizer used for the treatment of bipolar disorder, is associated with weight gain. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidepressants</strong> – There are many antidepressants which are associated with weight gain, including the tricyclics, monoamine oxidase inhibitors (MAOIs), and some of the selective serotonin reuptake inhibitors (SSRIs)  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Tricyclic antidepressants, in particular <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9283" href="/d/drug information/9283.html" rel="external">clomipramine</a>, <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a>, and <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a>, are associated with significant weight gain. (See  <a class="medical medical_review" href="/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">The effects of the SSRIs on body weight are less well characterized; the impact of these agents on weight is variable and may depend on the particular agent and the duration of use. Short-term use of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> has been associated with weight loss [<a href="#rid67">67,68</a>]. By contrast, long-term use of some, but not all, SSRIs may be associated with weight gain. As an example, in a randomized trial including 284 patients with depression receiving fluoxetine, sertraline, or <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> for 26 to 32 weeks, those receiving only the paroxetine group had a significant weight change compared with baseline (3.6 percent increase) [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Weight change'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure medications</strong> – Several antiseizure medications, particularly <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, used to treat seizures, neuropathic pain, and psychiatric conditions such as bipolar disorder, are associated with weight gain  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef132587" href="/d/graphic/132587.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Choosing an antiseizure medication'</a> and  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment", section on 'Choosing pharmacotherapy'</a> and  <a class="medical medical_review" href="/d/html/16847.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania"</a> and  <a class="medical medical_review" href="/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemic medications</strong> – Several medication classes used to treat diabetes are associated with modest weight gain, particularly insulin and the sulfonylureas  (<a class="graphic graphic_table graphicRef132587" href="/d/graphic/132587.html" rel="external">table 3</a>) [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">Compared with conventional insulin therapy, intensive insulin therapy results in greater weight gain. As an example, in the Diabetes Control and Complications Trial, the mean weight gain was greater in the intensive-treatment group compared with the usual care group (5.1 kg versus 2.4 kg) [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">The thiazolidinediones, such as <a class="drug drug_general" data-topicid="10216" href="/d/drug information/10216.html" rel="external">pioglitazone</a> and <a class="drug drug_general" data-topicid="10249" href="/d/drug information/10249.html" rel="external">rosiglitazone</a>, are also associated with weight gain, although this may be due to fluid retention and/or fat redistribution.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> does not cause weight gain and may be associated with weight loss. In the Diabetes Prevention Program, metformin was associated with modest, prolonged weight loss (approximately 2 kg) in patients with impaired glucose tolerance [<a href="#rid71">71</a>]. Other diabetes medications are either weight-neutral (ie, dipeptidyl peptidase-4 [DPP-4] inhibitors) or associated with more significant weight loss (ie, glucagon-like peptide 1 [GLP-1] receptor agonists, sodium-glucose co-transporter 2 [SGLT2] inhibitors, alpha-glucosidase inhibitors). The weight effects of diabetes medications are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1789.html" rel="external">"Insulin action"</a> and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Weight loss'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Weight loss'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal contraception</strong> – Although it is a common belief that oral contraceptives cause weight gain, data suggest that significant weight gain is not a common side effect of combined oral contraceptives at contemporary doses [<a href="#rid72">72</a>]. Progestin-only contraceptives, including depomedroxyprogesterone acetate (<a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>), are considered the hormonal contraceptive preparations most associated with weight gain [<a href="#rid73">73</a>], although a 2019 systematic review found no evidence to support a weight-gain relationship [<a href="#rid74">74</a>]. The variability in weight gain response to <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> contraceptives may be due to genetic variability. In a study including 276 participants using an <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a>, those who were homozygous for a particular estrogen receptor variant (ie, ESR1 rs9340799) experienced a 14.1 kg greater weight gain compared with those without the genetic variant [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1">Further details on specific hormonal contraception and weight gain are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Weight changes'</a> and  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)", section on 'Side effects'</a> and  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Weight gain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medications</strong> – Other drugs associated with weight gain include <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a> (an antihistamine), beta blockers, and glucocorticoids [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a> and  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H1977405782"><span class="h1">CONDITIONS ASSOCIATED WITH WEIGHT GAIN</span></p><p class="headingAnchor" id="H1967391759"><span class="h2">Hypothyroidism</span><span class="headingEndMark"> — </span>Patients with overt clinical hypothyroidism often gain weight, with some of the weight due to increased adiposity. The weight gain, however, is usually modest. Increasing serum thyroid-stimulating hormone (TSH) concentrations within the normal range have also been associated with a modest increase in body weight in adults [<a href="#rid76">76,77</a>], but treatment of subclinical hypothyroidism does not appear to be associated with weight loss. Observational data suggest that obesity may predispose to hypothyroidism, raising questions about causality [<a href="#rid78">78</a>]. Hypothyroidism and weight is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Potential consequences'</a> and  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H1409892582"><span class="h2">Cushing's syndrome</span><span class="headingEndMark"> — </span>A common feature in patients with Cushing’s syndrome is progressive central adiposity involving the trunk, abdomen, mesentery, and mediastinum. There is usually accumulation of fat tissue in the face and neck, with enlarged dorso- and supraclavicular fat pads. The extremities are usually spared and often exhibit muscular wasting. The excess of glucocorticoids in Cushing’s syndrome (iatrogenic or endogenous) induces 11-beta-hydroxysteroid dehydrogenase type 1 in visceral fat, enhancing its lipogenic capacity [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H2512482447"><span class="h2">Hypothalamic obesity</span><span class="headingEndMark"> — </span>Hypothalamic obesity is a rare syndrome in humans that can be reproduced in animals by injury to the ventromedial or paraventricular region of the hypothalamus or the amygdala [<a href="#rid80">80</a>]. These regions of the brain are responsible for integrating metabolic information regarding nutrient stores with afferent sensory information about food availability. When the ventromedial hypothalamus is damaged, hyperphagia develops, energy expenditure decreases [<a href="#rid81">81</a>], and obesity follows.</p><p>This syndrome can be caused by a tumor (most commonly craniopharyngioma) [<a href="#rid82">82</a>] (see  <a class="medical medical_review" href="/d/html/5210.html" rel="external">"Craniopharyngioma"</a>), trauma, irradiation, surgery in the posterior fossa, or increased intracranial pressure [<a href="#rid83">83</a>]. In addition to weight gain, additional symptoms may include headache, vomiting, and/or visual changes; amenorrhea, erectile dysfunction, arginine vasopressin deficiency (previously called central diabetes insipidus), hypothyroidism, and/or adrenal insufficiency; seizures, somnolence, coma, and/or disordered temperature regulation [<a href="#rid84">84</a>].</p><p>In a report of 42 adults with tumors in the hypothalamic region (treated with surgery and/or radiotherapy), 52 percent of patients had obesity after a median of five years of follow-up (versus 24 percent at baseline) [<a href="#rid85">85</a>]. In a multivariate analysis, no correlation was found between tumor location or size and subsequent weight gain.</p><p>Bariatric surgery has been found to produce moderate weight loss in patients with hypothalamic obesity, although the amount of weight lost may be less than what is seen in patients with "typical" obesity [<a href="#rid86">86,87</a>].</p><p class="headingAnchor" id="H2319222898"><span class="h2">Growth hormone deficiency</span><span class="headingEndMark"> — </span>Growth hormone deficiency in adults is associated with an increase in abdominal and visceral fat. (See  <a class="medical medical_review" href="/d/html/6641.html" rel="external">"Growth hormone deficiency in adults"</a>.)</p><p class="headingAnchor" id="H3599121748"><span class="h1">OTHER POSSIBLE CONTRIBUTORS TO OBESITY</span></p><p class="headingAnchor" id="H103932003"><span class="h2">The gut microbiome</span><span class="headingEndMark"> — </span>The composition of the gut flora, or the gut microbiome, may be a contributor to obesity. Since the observation that germ-free mice weigh less than mice with a normal gut microbiome [<a href="#rid88">88</a>], there have been a large number of studies demonstrating an association between the proportion of <em>Bacteroidetes</em> and <em>Firmicutes</em> bacteria in the gut and the development of obesity. It is less clear, however, that the relationship is causal [<a href="#rid89">89</a>]. The role of the gut microbiome in weight and obesity is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology", section on 'Gut microbiome'</a>.)</p><p class="headingAnchor" id="H1441180866"><span class="h2">Exposure to endocrine-disrupting chemicals</span><span class="headingEndMark"> — </span>Endocrine-disrupting chemicals are compounds that are used in the production of a wide range of commercial products. They have been found in environmental water samples and the food supply and can accumulate in human tissues. A growing number of studies have linked exposure to these compounds to both childhood and adult obesity [<a href="#rid90">90</a>]. Based on observational studies, bisphenol A and perfluorinated chemicals may be the most strongly associated [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H1658805527"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111344.html" rel="external">"Society guideline links: Obesity in adults"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83815.html" rel="external">"Patient education: Health risks of obesity (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15486.html" rel="external">"Patient education: Weight loss treatments (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1988.html" rel="external">"Patient education: Losing weight (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H66747156"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity as a disease</strong> – Obesity is the result of long-term positive energy balance where energy intake exceeds energy expenditure. It is now generally recognized that body weight is a physiologically regulated parameter, and obesity is recognized as a disease of body weight regulation. Studies suggest that the genetic contribution to adult body mass index (BMI) is 40 to 70 percent in most individuals. (See <a class="local">'Obesity as a disease'</a> above and <a class="local">'Genetics of obesity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age and weight</strong> – Prenatal and childhood factors, as well as weight trajectories observed with aging, can predispose to the development of adult obesity. Adults tend to gradually gain weight between the ages of 20 to 65, after which weight declines in most people  (<a class="graphic graphic_figure graphicRef132302" href="/d/graphic/132302.html" rel="external">figure 4</a>); this weight decline, however, is in part due to loss of muscle mass rather than adiposity. (See <a class="local">'Fetal and childhood factors'</a> above and <a class="local">'Weight gain in adulthood'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle contributors to obesity</strong> – Lifestyle factors, such as diet, physical activity (and inactivity), sleep patterns, and smoking cessation, are all associated with weight gain. (See <a class="local">'Lifestyle contributors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications associated with weight gain</strong> – A variety of common medications, including some antipsychotic agents, antidepressants, antiseizure medications, hypoglycemic agents, and hormonal contraceptives, have been associated with weight gain  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef132587" href="/d/graphic/132587.html" rel="external">table 3</a>). (See <a class="local">'Medications associated with weight gain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical conditions associated with weight gain</strong> – Certain medical conditions may be associated with weight gain, including hypothyroidism, Cushing’s syndrome, hypothalamic dysfunction (ie, hypothalamic obesity), and growth hormone deficiency. (See <a class="local">'Conditions associated with weight gain'</a> above.)</p><p></p><p class="headingAnchor" id="H1016648494"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George Bray, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev 2017; 38:267.</a></li><li><a class="nounderline abstract_t">Phelan SM, Burgess DJ, Yeazel MW, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev 2015; 16:319.</a></li><li><a class="nounderline abstract_t">Upadhyay J, Farr O, Perakakis N, et al. Obesity as a Disease. Med Clin North Am 2018; 102:13.</a></li><li><a class="nounderline abstract_t">Bray GA, Kim KK, Wilding JPH, World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017; 18:715.</a></li><li><a class="nounderline abstract_t">Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316:889.</a></li><li><a class="nounderline abstract_t">Loos RJ. The genetics of adiposity. Curr Opin Genet Dev 2018; 50:86.</a></li><li><a class="nounderline abstract_t">Whitaker KL, Jarvis MJ, Beeken RJ, et al. Comparing maternal and paternal intergenerational transmission of obesity risk in a large population-based sample. Am J Clin Nutr 2010; 91:1560.</a></li><li><a class="nounderline abstract_t">Rohde K, Keller M, la Cour Poulsen L, et al. Genetics and epigenetics in obesity. Metabolism 2019; 92:37.</a></li><li><a class="nounderline abstract_t">Huvenne H, Dubern B, Clément K, Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obes Facts 2016; 9:158.</a></li><li><a class="nounderline abstract_t">Scheinker D, Valencia A, Rodriguez F. Identification of Factors Associated With Variation in US County-Level Obesity Prevalence Rates Using Epidemiologic vs Machine Learning Models. JAMA Netw Open 2019; 2:e192884.</a></li><li><a class="nounderline abstract_t">Ogden CL, Fakhouri TH, Carroll MD, et al. Prevalence of Obesity Among Adults, by Household Income and Education - United States, 2011-2014. MMWR Morb Mortal Wkly Rep 2017; 66:1369.</a></li><li class="breakAll">Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief 2020:1. Available at: https://www.cdc.gov/nchs/products/databriefs/db360.htm (Accessed on December 18, 2020).</li><li><a class="nounderline abstract_t">von Hippel P, Benson R. Obesity and the natural environment across US counties. Am J Public Health 2014; 104:1287.</a></li><li><a class="nounderline abstract_t">Drewnowski A. The economics of food choice behavior: why poverty and obesity are linked. Nestle Nutr Inst Workshop Ser 2012; 73:95.</a></li><li><a class="nounderline abstract_t">Fernandez-Twinn DS, Hjort L, Novakovic B, et al. Intrauterine programming of obesity and type 2 diabetes. Diabetologia 2019; 62:1789.</a></li><li><a class="nounderline abstract_t">Fall CHD, Kumaran K. Metabolic programming in early life in humans. Philos Trans R Soc Lond B Biol Sci 2019; 374:20180123.</a></li><li><a class="nounderline abstract_t">Hieronimus B, Ensenauer R. Influence of maternal and paternal pre-conception overweight/obesity on offspring outcomes and strategies for prevention. Eur J Clin Nutr 2021; 75:1735.</a></li><li><a class="nounderline abstract_t">Josefson JL, Catalano PM, Lowe WL, et al. The Joint Associations of Maternal BMI and Glycemia with Childhood Adiposity. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Şanlı E, Kabaran S. Maternal Obesity, Maternal Overnutrition and Fetal Programming: Effects of Epigenetic Mechanisms on the Development of Metabolic Disorders. Curr Genomics 2019; 20:419.</a></li><li><a class="nounderline abstract_t">Vasan RS, Pencina MJ, Cobain M, et al. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med 2005; 143:473.</a></li><li><a class="nounderline abstract_t">Bessesen DH. Regulation of body weight: what is the regulated parameter? Physiol Behav 2011; 104:599.</a></li><li><a class="nounderline abstract_t">Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299:853.</a></li><li><a class="nounderline abstract_t">Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992; 327:1893.</a></li><li><a class="nounderline abstract_t">Trabulsi J, Schoeller DA. Evaluation of dietary assessment instruments against doubly labeled water, a biomarker of habitual energy intake. Am J Physiol Endocrinol Metab 2001; 281:E891.</a></li><li><a class="nounderline abstract_t">Yang YC, Walsh CE, Johnson MP, et al. Life-course trajectories of body mass index from adolescence to old age: Racial and educational disparities. Proc Natl Acad Sci U S A 2021; 118.</a></li><li><a class="nounderline abstract_t">Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14:513.</a></li><li><a class="nounderline abstract_t">Elia M. Obesity in the elderly. Obes Res 2001; 9 Suppl 4:244S.</a></li><li><a class="nounderline abstract_t">Mannan M, Doi SA, Mamun AA. Association between weight gain during pregnancy and postpartum weight retention and obesity: a bias-adjusted meta-analysis. Nutr Rev 2013; 71:343.</a></li><li><a class="nounderline abstract_t">Smith DE, Lewis CE, Caveny JL, et al. Longitudinal changes in adiposity associated with pregnancy. The CARDIA Study. Coronary Artery Risk Development in Young Adults Study. JAMA 1994; 271:1747.</a></li><li><a class="nounderline abstract_t">Gunderson EP, Sternfeld B, Wellons MF, et al. Childbearing may increase visceral adipose tissue independent of overall increase in body fat. Obesity (Silver Spring) 2008; 16:1078.</a></li><li><a class="nounderline abstract_t">Kominiarek MA, Peaceman AM. Gestational weight gain. Am J Obstet Gynecol 2017; 217:642.</a></li><li><a class="nounderline abstract_t">Deputy NP, Sharma AJ, Kim SY, Hinkle SN. Prevalence and characteristics associated with gestational weight gain adequacy. Obstet Gynecol 2015; 125:773.</a></li><li><a class="nounderline abstract_t">Kapoor E, Collazo-Clavell ML, Faubion SS. Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management. Mayo Clin Proc 2017; 92:1552.</a></li><li><a class="nounderline abstract_t">Van Pelt RE, Gavin KM, Kohrt WM. Regulation of Body Composition and Bioenergetics by Estrogens. Endocrinol Metab Clin North Am 2015; 44:663.</a></li><li><a class="nounderline abstract_t">Kohrt WM, Wierman ME. Preventing Fat Gain by Blocking Follicle-Stimulating Hormone. N Engl J Med 2017; 377:293.</a></li><li><a class="nounderline abstract_t">Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007; 92:895.</a></li><li><a class="nounderline abstract_t">Chen Z, Bassford T, Green SB, et al. Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative. Am J Clin Nutr 2005; 82:651.</a></li><li><a class="nounderline abstract_t">Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997; 82:1549.</a></li><li><a class="nounderline abstract_t">Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev 2000; :CD001018.</a></li><li><a class="nounderline abstract_t">Swinburn B, Sacks G, Ravussin E. Increased food energy supply is more than sufficient to explain the US epidemic of obesity. Am J Clin Nutr 2009; 90:1453.</a></li><li class="breakAll">Dietary guidelines for Americans 2020-2025 https://www.dietaryguidelines.gov/ (Accessed on June 29, 2021).</li><li><a class="nounderline abstract_t">Mozaffarian D, Hao T, Rimm EB, et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011; 364:2392.</a></li><li><a class="nounderline abstract_t">Rauber F, Steele EM, Louzada MLDC, et al. Ultra-processed food consumption and indicators of obesity in the United Kingdom population (2008-2016). PLoS One 2020; 15:e0232676.</a></li><li><a class="nounderline abstract_t">Hall KD, Ayuketah A, Brychta R, et al. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab 2019; 30:67.</a></li><li><a class="nounderline abstract_t">Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA 2018; 320:2020.</a></li><li class="breakAll">US Department of Health and Human Services. Physical activity and health: A report of the Surgeon General. 1996. Available at: https://www.cdc.gov/nccdphp/sgr/pdf/sgrfull.pdf (Accessed on September 01, 2021).</li><li><a class="nounderline abstract_t">Esparza J, Fox C, Harper IT, et al. Daily energy expenditure in Mexican and USA Pima indians: low physical activity as a possible cause of obesity. Int J Obes Relat Metab Disord 2000; 24:55.</a></li><li><a class="nounderline abstract_t">Church TS, Thomas DM, Tudor-Locke C, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One 2011; 6:e19657.</a></li><li><a class="nounderline abstract_t">Maher CA, Mire E, Harrington DM, et al. The independent and combined associations of physical activity and sedentary behavior with obesity in adults: NHANES 2003-06. Obesity (Silver Spring) 2013; 21:E730.</a></li><li><a class="nounderline abstract_t">Campbell SDI, Brosnan BJ, Chu AKY, et al. Sedentary Behavior and Body Weight and Composition in Adults: A Systematic Review and Meta-analysis of Prospective Studies. Sports Med 2018; 48:585.</a></li><li><a class="nounderline abstract_t">Katzmarzyk PT, Church TS, Craig CL, Bouchard C. Sitting time and mortality from all causes, cardiovascular disease, and cancer. Med Sci Sports Exerc 2009; 41:998.</a></li><li><a class="nounderline abstract_t">Hu FB, Li TY, Colditz GA, et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003; 289:1785.</a></li><li><a class="nounderline abstract_t">Borghese MM, Tremblay MS, Leduc G, et al. Independent and combined associations of total sedentary time and television viewing time with food intake patterns of 9- to 11-year-old Canadian children. Appl Physiol Nutr Metab 2014; 39:937.</a></li><li><a class="nounderline abstract_t">Bellisle F. Meals and snacking, diet quality and energy balance. Physiol Behav 2014; 134:38.</a></li><li><a class="nounderline abstract_t">Weil E, Wachterman M, McCarthy EP, et al. Obesity among adults with disabling conditions. JAMA 2002; 288:1265.</a></li><li><a class="nounderline abstract_t">McHill AW, Wright KP Jr. Role of sleep and circadian disruption on energy expenditure and in metabolic predisposition to human obesity and metabolic disease. Obes Rev 2017; 18 Suppl 1:15.</a></li><li><a class="nounderline abstract_t">Tse LA, Wang C, Rangarajan S, et al. Timing and Length of Nocturnal Sleep and Daytime Napping and Associations With Obesity Types in High-, Middle-, and Low-Income Countries. JAMA Netw Open 2021; 4:e2113775.</a></li><li><a class="nounderline abstract_t">Youngstedt SD, Goff EE, Reynolds AM, et al. Has adult sleep duration declined over the last 50+ years? Sleep Med Rev 2016; 28:69.</a></li><li><a class="nounderline abstract_t">Arble DM, Bass J, Behn CD, et al. Impact of Sleep and Circadian Disruption on Energy Balance and Diabetes: A Summary of Workshop Discussions. Sleep 2015; 38:1849.</a></li><li><a class="nounderline abstract_t">Markwald RR, Melanson EL, Smith MR, et al. Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain. Proc Natl Acad Sci U S A 2013; 110:5695.</a></li><li><a class="nounderline abstract_t">Reutrakul S, Van Cauter E. Sleep influences on obesity, insulin resistance, and risk of type 2 diabetes. Metabolism 2018; 84:56.</a></li><li><a class="nounderline abstract_t">Tasali E, Wroblewski K, Kahn E, et al. Effect of Sleep Extension on Objectively Assessed Energy Intake Among Adults With Overweight in Real-life Settings: A Randomized Clinical Trial. JAMA Intern Med 2022; 182:365.</a></li><li><a class="nounderline abstract_t">Bush T, Lovejoy JC, Deprey M, Carpenter KM. The effect of tobacco cessation on weight gain, obesity, and diabetes risk. Obesity (Silver Spring) 2016; 24:1834.</a></li><li><a class="nounderline abstract_t">Mineur YS, Abizaid A, Rao Y, et al. Nicotine decreases food intake through activation of POMC neurons. Science 2011; 332:1330.</a></li><li><a class="nounderline abstract_t">Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100:342.</a></li><li><a class="nounderline abstract_t">Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100:395.</a></li><li><a class="nounderline abstract_t">Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100:363.</a></li><li><a class="nounderline abstract_t">Rachdi C, Damak R, Fekih Romdhane F, et al. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. Prim Care Diabetes 2019; 13:57.</a></li><li><a class="nounderline abstract_t">Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863.</a></li><li><a class="nounderline abstract_t">Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988; 11:567.</a></li><li><a class="nounderline abstract_t">Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.</a></li><li><a class="nounderline abstract_t">Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014; :CD003987.</a></li><li><a class="nounderline abstract_t">Dianat S, Fox E, Ahrens KA, et al. Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate: A Systematic Review. Obstet Gynecol 2019; 133:332.</a></li><li><a class="nounderline abstract_t">Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2016; :CD008815.</a></li><li><a class="nounderline abstract_t">Lazorwitz A, Dindinger E, Harrison M, et al. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020; 102:180.</a></li><li><a class="nounderline abstract_t">Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90:4019.</a></li><li><a class="nounderline abstract_t">Fox CS, Pencina MJ, D'Agostino RB, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med 2008; 168:587.</a></li><li><a class="nounderline abstract_t">Rotondi M, Magri F, Chiovato L. Thyroid and obesity: not a one-way interaction. J Clin Endocrinol Metab 2011; 96:344.</a></li><li><a class="nounderline abstract_t">Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36:146.</a></li><li><a class="nounderline abstract_t">Hochberg I, Hochberg Z. Expanding the definition of hypothalamic obesity. Obes Rev 2010; 11:709.</a></li><li><a class="nounderline abstract_t">Holmer H, Pozarek G, Wirfält E, et al. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab 2010; 95:5395.</a></li><li><a class="nounderline abstract_t">Rose SR, Horne VE, Bingham N, et al. Hypothalamic Obesity: 4 Years of the International Registry of Hypothalamic Obesity Disorders. Obesity (Silver Spring) 2018; 26:1727.</a></li><li><a class="nounderline abstract_t">Bray GA. Syndromes of hypothalamic obesity in man. Pediatr Ann 1984; 13:525.</a></li><li><a class="nounderline abstract_t">Bray GA, Gallagher TF Jr. Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a reveiw of the literature. Medicine (Baltimore) 1975; 54:301.</a></li><li><a class="nounderline abstract_t">Daousi C, Dunn AJ, Foy PM, et al. Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 2005; 118:45.</a></li><li><a class="nounderline abstract_t">van Santen SS, Wolf P, Kremenevski N, et al. Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. J Clin Endocrinol Metab 2021; 106:e4734.</a></li><li><a class="nounderline abstract_t">Bretault M, Boillot A, Muzard L, et al. Clinical review: Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J Clin Endocrinol Metab 2013; 98:2239.</a></li><li><a class="nounderline abstract_t">Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027.</a></li><li><a class="nounderline abstract_t">Maruvada P, Leone V, Kaplan LM, Chang EB. The Human Microbiome and Obesity: Moving beyond Associations. Cell Host Microbe 2017; 22:589.</a></li><li><a class="nounderline abstract_t">Gore AC, Chappell VA, Fenton SE, et al. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev 2015; 36:E1.</a></li><li><a class="nounderline abstract_t">Kahn LG, Philippat C, Nakayama SF, et al. Endocrine-disrupting chemicals: implications for human health. Lancet Diabetes Endocrinol 2020; 8:703.</a></li></ol></div><div id="topicVersionRevision">Topic 5377 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28898979" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Obesity Pathogenesis: An Endocrine Society Scientific Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25752756" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of weight bias and stigma on quality of care and outcomes for patients with obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29156181" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Obesity as a Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28489290" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29529423" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The genetics of adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375189" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparing maternal and paternal intergenerational transmission of obesity risk in a large population-based sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30399374" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Genetics and epigenetics in obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27241181" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31026030" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of Factors Associated With Variation in US County-Level Obesity Prevalence Rates Using Epidemiologic vs Machine Learning Models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29267260" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of Obesity Among Adults, by Household Income and Education - United States, 2011-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29267260" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of Obesity Among Adults, by Household Income and Education - United States, 2011-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24832148" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Obesity and the natural environment across US counties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128769" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The economics of food choice behavior: why poverty and obesity are linked.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31451874" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intrauterine programming of obesity and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30966889" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Metabolic programming in early life in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34131301" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Influence of maternal and paternal pre-conception overweight/obesity on offspring outcomes and strategies for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271383" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Joint Associations of Maternal BMI and Glycemia with Childhood Adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476999" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Maternal Obesity, Maternal Overnutrition and Fetal Programming: Effects of Epigenetic Mechanisms on the Development of Metabolic Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204159" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Estimated risks for developing obesity in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565211" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Regulation of body weight: what is the regulated parameter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12574618" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Obesity and the environment: where do we go from here?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1454084" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Discrepancy between self-reported and actual caloric intake and exercise in obese subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11595643" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of dietary assessment instruments against doubly labeled water, a biomarker of habitual energy intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33875595" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Life-course trajectories of body mass index from adolescence to old age: Racial and educational disparities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30065268" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11707549" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Obesity in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23731445" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association between weight gain during pregnancy and postpartum weight retention and obesity: a bias-adjusted meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196117" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Longitudinal changes in adiposity associated with pregnancy. The CARDIA Study. Coronary Artery Risk Development in Young Adults Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356843" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Childbearing may increase visceral adipose tissue independent of overall increase in body fat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28549978" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gestational weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25751216" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence and characteristics associated with gestational weight gain adequacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28982486" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316249" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Regulation of Body Composition and Bioenergetics by Estrogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723332" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Preventing Fat Gain by Blocking Follicle-Stimulating Hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192296" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Changes in body composition in women over six years at midlife: ovarian and chronological aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16155280" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141548" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796730" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828708" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Increased food energy supply is more than sufficient to explain the US epidemic of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828708" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased food energy supply is more than sufficient to explain the US epidemic of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21696306" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Changes in diet and lifestyle and long-term weight gain in women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32357191" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ultra-processed food consumption and indicators of obesity in the United Kingdom population (2008-2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31105044" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418471" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Physical Activity Guidelines for Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418471" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The Physical Activity Guidelines for Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10702751" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Daily energy expenditure in Mexican and USA Pima indians: low physical activity as a possible cause of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21647427" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512825" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The independent and combined associations of physical activity and sedentary behavior with obesity in adults: NHANES 2003-06.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189928" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sedentary Behavior and Body Weight and Composition in Adults: A Systematic Review and Meta-analysis of Prospective Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19346988" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sitting time and mortality from all causes, cardiovascular disease, and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684356" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24892903" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Independent and combined associations of total sedentary time and television viewing time with food intake patterns of 9- to 11-year-old Canadian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657181" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Meals and snacking, diet quality and energy balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12215134" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Obesity among adults with disabling conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28164449" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of sleep and circadian disruption on energy expenditure and in metabolic predisposition to human obesity and metabolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34190997" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Timing and Length of Nocturnal Sleep and Daytime Napping and Associations With Obesity Types in High-, Middle-, and Low-Income Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26478985" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Has adult sleep duration declined over the last 50+ years?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26564131" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of Sleep and Circadian Disruption on Energy Balance and Diabetes: A Summary of Workshop Discussions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23479616" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29510179" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sleep influences on obesity, insulin resistance, and risk of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35129580" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of Sleep Extension on Objectively Assessed Energy Intake Among Adults With Overweight in Real-life Settings: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27569117" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effect of tobacco cessation on weight gain, obesity, and diabetes risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659607" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nicotine decreases food intake through activation of POMC neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590212" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacological management of obesity: an endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17566010" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590213" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287230" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11105740" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904881" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11832527" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477630" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Combination contraceptives: effects on weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30633132" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27567593" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Progestin-only contraceptives: effects on weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407811" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870128" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362250" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296993" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Thyroid and obesity: not a one-way interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230901" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : 11beta-hydroxysteroid dehydrogenase type 1 and obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233310" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Expanding the definition of hypothalamic obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826582" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30296362" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hypothalamic Obesity: 4 Years of the International Registry of Hypothalamic Obesity Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6382132" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Syndromes of hypothalamic obesity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1152672" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a reveiw of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639209" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265053" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23533238" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical review: Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17183312" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : An obesity-associated gut microbiome with increased capacity for energy harvest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29120742" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The Human Microbiome and Obesity: Moving beyond Associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26544531" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707118" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Endocrine-disrupting chemicals: implications for human health.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
